Combination Antiglaucoma Ophthalmic Therapies for Dogs in Canada 2026 — Top 5 Fixed-Combinations (Cosopt, Combigan, Azarga, DuoTrav, Xalacom) and What Canadian Vets Recommend
Published on Monday, February 2, 2026
Fixed combination antiglaucoma eye drops combine two complementary mechanisms of action — for example a beta blocker with a carbonic anhydrase inhibitor or a prostaglandin analog with a beta blocker — to improve intraocular pressure control and simplify dosing for dogs. In Canada, owners and veterinarians increasingly prefer fixed combinations because they reduce the number of separate bottles and administrations, often improve adherence, and can lower overall treatment complexity and cost compared with multiple single-agent prescriptions. Availability, off-label use in veterinary practice, compounding options, and growing veterinary telemedicine services also shape purchasing and prescribing choices in 2026. While many formulations are originally developed for humans, veterinary clinicians choose combinations based on efficacy, tolerability, ease of administration, and clinical monitoring needs for canine patients.
Top Picks Summary
Cosopt (dorzolamide-timolol)
Cosopt is a long-established carbonic anhydrase inhibitor + beta‑blocker combination that is frequently chosen for canine glaucoma because it delivers consistent aqueous suppression without relying on prostaglandin pathways. Its mature market presence and availability of lower‑cost generics often make it the most economical first‑line combination compared with newer proprietary formulations like DuoTrav or Azarga, while offering a complementary mechanism to alpha‑agonist combinations such as Combigan.
What the Research Shows: Efficacy and Safety of Fixed Combination Antiglaucoma Drops
Clinical data and experimental studies indicate that combining two intraocular pressure lowering agents can produce additive or synergistic reductions in intraocular pressure (IOP) compared with monotherapy, while reducing the number of daily administrations and improving owner adherence. Evidence directly in dogs is more limited than in human ophthalmology, so veterinarians typically rely on a combination of canine clinical studies, pharmacology, and human trial evidence when choosing a regimen. Key scientific principles are straightforward: carbonic anhydrase inhibitors and beta blockers reduce aqueous production, while prostaglandin analogs increase uveoscleral outflow; pairing agents with different mechanisms achieves stronger IOP control. Safety profiles differ by agent class, so veterinary oversight and regular IOP and ocular examinations are essential.
Multiple studies show fixed combinations (beta blocker + carbonic anhydrase inhibitor or prostaglandin analog + beta blocker) achieve greater mean IOP reduction than single-agent therapy in short-term trials.
Small canine clinical reports and case series report meaningful IOP reductions with Cosopt (dorzolamide-timolol) and Azarga (brinzolamide-timolol), though large randomized controlled trials in dogs are limited.
Human randomized trials support improved adherence and comparable safety for fixed combinations versus separate bottles; similar adherence benefits are reported anecdotally in veterinary settings.
Prostaglandin-containing combinations (DuoTrav, Xalacom) are often the most potent IOP-lowering options but can cause miosis, ocular hyperemia, and are used cautiously in certain canine patients.
Brimonidine-containing combinations (Combigan) may offer nocturnal IOP benefits in some studies but can be more prone to systemic side effects in sensitive patients.
Pharmacologic interactions and systemic absorption (especially of beta blockers) require monitoring in dogs with cardiac or respiratory disease; vet supervision is needed for dose selection and safety checks.
Frequently Asked Questions
Which fixed-combination is best for most dogs glaucoma?
For most dogs needing consistent pressure control without prostaglandin pathways, vets commonly choose Cosopt (dorzolamide-timolol), a carbonic anhydrase inhibitor plus beta-blocker dual aqueous suppression option rated 4.1.
What exact ingredients and dosing does Combigan use?
Combigan pairs brimonidine (alpha-2 agonist) with timolol (beta-blocker) to reduce aqueous production and increase outflow signaling, and it’s usually dosed twice daily off-label in dogs, rated 3.8.
How does Azarga’s price value compare to Cosopt?
Price info isn’t provided for Azarga or Cosopt in the data, but Azarga (brinzolamide-timolol) is rated 4.0 and uses a suspension brinzolamide plus timolol formulation that may cause transient blurring.
Can dogs use Cosopt or Combigan safely long-term?
Safety guidance in the data is off-label monitoring: Cosopt may cause systemic beta-blocker effects like bradycardia and bronchospasm, and Combigan has risks like sedation, hypotension, or respiratory depression; no warranty duration is provided.
Conclusion
In the Canadian 2026 context, fixed combination antiglaucoma drops remain a pragmatic choice for many canine glaucoma patients because they combine effectiveness with simpler dosing. The five main combinations discussed here — Cosopt (dorzolamide-timolol), Combigan (brimonidine-timolol), Azarga (brinzolamide-timolol), DuoTrav (travoprost-timolol), and Xalacom (latanoprost-timolol) — each have practical advantages depending on the dog’s condition and comorbidities. For many practitioners Cosopt (dorzolamide-timolol) is often selected as the best first-line fixed combination because of its predictable IOP-lowering profile, tolerability in dogs, and broad availability in Canada, while prostaglandin-containing options such as DuoTrav or Xalacom are reserved for cases needing stronger outflow-enhancing therapy. Combigan and Azarga are useful alternatives where specific agent properties or tolerability favor their use. We hope you found the information you were looking for; you can refine or expand your search by product name, ingredient, or by consulting your veterinarian for a tailored plan appropriate to your dog’s needs.